OSLO (Reuters) -Novo Nordisk said on Friday it plans to invest more than 42 billion crowns ($6 billion) in the coming years as it seeks to meet booming demand for its Wegovy weight-loss treatment and other drugs.
The investment in expanding its Kalundborg production unit in Denmark will boost capacity across the company's value chain from active pharmaceutical ingredients (API) manufacturing to packaging, with the bulk invested in API capacity.
Novo Nordisk said in a statement investments include an expansion of its capacity for GLP-1 products, which include the active ingredients in Wegovy as well as the company's Ozempic diabetes treatment.
"Our continued investment in global capacity demonstrates the belief we have in our current and future product portfolio," said Henrik Wulff, Novo's head of Product Supply, Quality & IT.
A portion of the investment was included in a 25 billion crowns capital expenditure announced in February, Novo said.
The construction projects will be finalised gradually from the end of 2025 through 2029.
($1 = 6.9904 Danish crowns)
(Reporting by Terje Solsvik, editing by Essi Lehto and Anna Ringstrom)
